Abstract: An organ perfusion and preservation system for use in preserving an organ from a donor, may include a fluid reservoir, a heat exchanger in fluid communication with the fluid reservoir and configured to selectively raise and lower a temperature of a perfusion fluid, an oxygenator configured to oxygenate the perfusion fluid, an inflow pump in fluid communication with the fluid reservoir and the oxygenator, a fluid inflow line configured to transport perfusion fluid from the oxygenator to the organ, a fluid outflow line configured to transport perfusion fluid away from the organ and back to the reservoir, an outflow pump in fluid communication with the fluid outflow line and the fluid reservoir, and a controller operatively connected to the inflow pump, the outflow pump, and the heat exchanger, wherein the controller is configured to select parameters to reversibly heat and reversibly cool the organ.

Abstract: A magnetic locking device for a pipetting tool, the device having a plate that is able to be adapted to the pipetting tool, an accessory being intended to be fastened to a fastening end piece that is supported by the plate and/or intended to be supported by the pipetting tool. The device has at least one lock configured to switch from an active state to a passive state, and vice versa, such that, in the active state, the lock is able to block, in service, particles that are present in the accessory, and such that, in the passive state of the lock, the particles are free to move in the accessory.

Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29a-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.

Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.

Abstract: A method for characterizing an anisotropic soft medium (C) including fibers and having an outer surface (1), by observing in different propagation directions, the propagation of a divergent shear wave from a central area (10) in the anisotropic soft medium. A propagation parameter of the shear wave is inferred therefrom in each of the propagation directions, and then a direction of the fibers of the anisotropic soft medium, a rheological elasticity parameter are determined in a direction perpendicular to the fibers and a rheological elasticity parameter in the direction of the fibers.

Abstract: This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.

Abstract: The present invention concerns a method for obtaining a functional parameter of a muscle having a part, the method comprising the steps of: a) applying ultrasound waves to the muscle, b) collecting the ultrasound waves retrodiffused by the muscle at a plurality of times, to obtain collected ultrasound waves, c) determining a first plurality of values representative of stiffness values of one part at a first plurality of times by using the collected ultrasound waves, d) determining a second plurality of values representative of deformation values of said part at a second plurality of times by using the collected ultrasound waves, and e) deducing at least one functional parameter based on the first plurality of values and the second plurality of values. The invention also concerns a corresponding device.

Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.

Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.

Abstract: The present invention concerns a laser scanning system (18) comprising: —a first acousto-optical deflector (30) deflecting a beam in a first direction (X) to obtain a first deflected beam and comprising a first acousto-optical crystal on which is applied an acoustic wave whose frequency varies over time according to a first law of command, and —a second acousto-optical deflector (32) deflected the first deflected beam in a second direction (Y), defining an angle comprised between 85° and 95° with the first direction, and comprising a second acousto-optical crystal on which is applied an acoustic wave whose frequency varies over time according to a second law of command, characterized in that the first law of command and the second law of command are chosen so that the average speed of the laser scanning system (18) is superior to 10 radians per second.

Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.

Abstract: The object of the invention relates to an apparatus for the thermal treatment of biological tissues by means of the application of focused ultrasound waves, the apparatus including: a probe movement system for ensuring: the moving of the focal zone along a first direction, from a distal point of the treatment zone to a proximal point of the treatment zone, in order to create a sequence of elementary treatment zones; the juxtaposition of sequences of elementary treatment zones in order to completely cover the treatment zone; a control circuit controlling the probe, in order to ensure that the ultrasonic power delivered to the focal zone decreases between the distal point and the proximal point of the treatment zone.

Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.

Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

Abstract: The present invention concerns a method for obtaining a functional parameter of a muscle having a part, the method comprising the steps of: a) applying ultrasound waves to the muscle, b) collecting the ultrasound waves retrodiffused by the muscle at a plurality of times, to obtain collected ultrasound waves, c) determining a first plurality of values representative of stiffness values of one part at a first plurality of times by using the collected ultrasound waves, d) determining a second plurality of values representative of deformation values of said part at a second plurality of times by using the collected ultrasound waves, and e) deducing at least one functional parameter based on the first plurality of values and the second plurality of values. The invention also concerns a corresponding device.

Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.

Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.

Abstract: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.

Abstract: Provided are compounds of formula (I): wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6 alkylene radical, notably useful for the treatment of human cancers.

Abstract: Cyclic beta glucan compounds function as an immunoadjuvant when administered prior to, concommitantly with, or subsequent to the administration of one or more antigens to a subject. These adjuvant compounds may be effectively used as dendritic cell activating molecules.